文献速递系统性红斑狼疮

血浆C4d水平与增生性狼疮肾炎的治疗反应及肾脏活动度相关

Plasma C4d levels correlate with treatment response and renal activity in proliferative lupus nephritis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

纳入77例经肾活检确诊的活动性狼疮肾炎患者,在免疫抑制治疗前后两个活检时间点评估补体C3、C4、C4d及C4d/C4比值,并检测C4基因拷贝数变异。结果显示治疗应答的增生性狼疮肾炎患者C3、C4升高而C4d、C4d/C4下降;第二次活检时C4d及C4d/C4与临床和病理应答相关,C4基因变异与应答无关。

要点

  • 治疗应答的增生性狼疮肾炎患者C3、C4升高,C4d及C4d/C4下降(P < 0.0001)。
  • 第二次活检时C4d、C4及C4d/C4与增生性狼疮肾炎临床应答相关。
  • 病理应答的增生性狼疮肾炎患者C4d水平较低(P = 0.008)。

核心结论

  • 所有补体标志物均受免疫抑制治疗影响并与治疗应答相关。
  • 随访活检中C4d及C4d/C4水平与增生性狼疮肾炎的临床和病理应答均呈强关联。
  • 重复活检中C4d及C4d/C4升高与持续高活动度指数相关,支持C4d作为增生性狼疮肾炎治疗应答的有前景生物标志物。
  • C4基因变异不影响C4水平或治疗应答。

研究设计与样本

  • 纳入77例经肾活检确诊的活动性狼疮肾炎患者,均在免疫抑制治疗后进行了第二次活检。
  • 在两次活检时间点评估补体C3、C4、C4d及C4d/C4比值。
  • 同时检测C4基因(C4A和C4B)拷贝数变异。

主要发现

  • 基线时60例为III/IV±V型增生性狼疮肾炎(PLN),17例为V型膜性狼疮肾炎(MLN)。
  • 治疗后C3和C4升高、C4d和C4d/C4下降(P < 0.0001),该变化见于治疗应答的PLN患者,未见于此MLN患者。
  • 第二次活检时C4d、C4及C4d/C4与PLN临床应答相关,病理应答的PLN患者C4d水平较低(P = 0.008)。
  • 第二次活检时肾脏活动度指数与C4d及C4d/C4相关,但与C3或C4无关。
  • C4基因拷贝数变异与临床或病理应答均无关。

关键数值与推荐

  • 治疗后C3和C4升高、C4d和C4d/C4下降,P < 0.0001,见于治疗应答的PLN患者。
  • 病理应答的PLN患者C4d水平较低,P = 0.008。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The investigation of complement factors in lupus nephritis (LN) in relation to treatment response and the impact of underlying genetics of C4. METHODS: Seventy-seven patients with active LN confirmed by a kidney biopsy and in whom second biopsies had been performed after immunosuppressive treatment were included. Complement factors C3, C4, C4d and C4d/C4 ratio were evaluated at the biopsy time points. The gene copy number variations of C4 (C4A and C4B) were also investigated. RESULTS: At baseline, 60 patients had class III/IV±V, proliferative LN (PLN) and 17 class V, membranous LN (MLN). Levels of C3 and C4 increased and C4d and C4d/C4 decreased after treatment (P < 0.0001), observed in treatment-responding PLN patients but not in MLN. C4d, C4 and C4d/C4 at second biopsies were associated with clinical response in PLN, and low C4d levels were found in PLN with histopathological response (P = 0.008). Renal activity index at second biopsies correlated to C4d and C4d/C4, but not to C3 or C4. C4 gene copy number variations were not associated with clinical or histopathological response. CONCLUSION: All complement markers were affected by immunosuppressive therapy and associated with response to therapy. Levels of C4d and C4d/C4 at follow-up biopsies showed a strong association with both clinical and histopathological response in PLN. The correlation with elevated C4d and C4d/C4 and persisting high activity index on repeated biopsies strengthens the findings on C4d as a promising biomarker for treatment response in PLN. The C4 genetic variations did not influence C4 levels or response to treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Zickert A, Grönwall C, Juto A, et al. Plasma C4d levels correlate with treatment response and renal activity in proliferative lupus nephritis. Rheumatology (Oxford). 2025. PMID: 40280868. doi:10.1093/rheumatology/keaf160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。